(+)-Grandifloracin, an antiausterity agent, induces autophagic PANC-1 pancreatic cancer cell death

References

• Asuthkar S Rao JS Gondi CS Drugs in preclinical and early-stage clinical development for pancreatic cancer Expert Opin Investig Drugs 2012 21 143 152
   PubMed Web of Science ®Google Scholar
• The Editorial Board of the Cancer Statistics in Japan Cancer Statistics in Japan 2012 Tokyo, Japan Foundation for Promotion Cancer Research 2012
   Google Scholar
• Hidalgo M Pancreatic cancer N Engl J Med 2010 362 1605 1617 20427809
   PubMed Web of Science ®Google Scholar
• Jemal A Bray F Center MM Ferlay J Ward E Forman D Global cancer statistics CA Cancer J Clin 2011 61 69 90 21296855
   PubMed Web of Science ®Google Scholar
• Lionetto R Pugliese V Bruzzi P Rosso R No standard treatment is available for advanced pancreatic cancer Eur J Cancer 1995 31 882 887 7646915
   PubMed Web of Science ®Google Scholar
• Philip PA Benedetti J Corless CL Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest oncology group-directed intergroup trial S0205 J Clin Oncol 2010 28 3605 3610 20606093
   PubMed Web of Science ®Google Scholar
• Arumugam T Ramachandran V Fournier KF Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer Cancer Res 2009 69 5820 5828 19584296
   PubMed Web of Science ®Google Scholar
• Qiu MT Ding XX Hu JW Tian HY Yin R Xu L Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced non-small-cell lung cancer: a meta-analysis of six trials Cancer Chemother Pharmacol 2012 70 861 873 23053260
   PubMed Web of Science ®Google Scholar
• Conroy T Desseigne F Ychou M FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 2011 364 1817 1825 21561347
   PubMed Web of Science ®Google Scholar
• Von Hoff DD Ramanathan RK Borad MJ Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial J Clin Oncol 2011 29 4548 4554 21969517
   PubMed Web of Science ®Google Scholar
• Ko AH Venook AP Bergsland EK A Phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer Cancer Chemother Pharmacol 2010 66 1051 1057 20130876
   PubMed Web of Science ®Google Scholar
• Sakamoto H Kitano M Suetomi Y Maekawa K Takeyama Y Kudo M Utility of contrast-enhanced endoscopic ultrasonography for diagnosis of small pancreatic carcinomas Ultrasound Med Biol 2008 34 525 532 18045768
   PubMed Web of Science ®Google Scholar
• Feig C Gopinathan A Neesse A Chan DS Cook N Tuveson DA The pancreas cancer microenvironment Clin Cancer Res 2012 18 4266 4276 22896693
   PubMed Web of Science ®Google Scholar
• Izuishi K Kato K Ogura T Kinoshita T Esumi H Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy Cancer Res 2000 60 6201 6207 11085546
   PubMed Web of Science ®Google Scholar
• Awale S Lu J Kalauni SK Identification of arctigenin as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation Cancer Res 2006 66 1751 1757 16452235
   PubMed Web of Science ®Google Scholar
• Awale S Nakashima EMN Kalauni SK Angelmarin, a novel anti-cancer agent able to eliminate the tolerance of cancer cells to nutrient starvation Bioorg Med Chem Lett 2006 16 581 583 16288865
   PubMed Web of Science ®Google Scholar
• Win NN Awale S Esumi H Tezuka Y Kadota S Novel anticancer agents, kayeassamins A and B from the flower of Kayea assamica of Myanmar Bioorg Med Chem Lett 2008 18 4688 4691 18640837
   PubMed Web of Science ®Google Scholar
• Win NN Awale S Esumi H Tezuka Y Kadota S Novel anticancer agents, kayeassamins C–I from the flower of Kayea assamica of Myanmar Bioorg Med Chem 2008 16 8653 8660 18725180
   PubMed Web of Science ®Google Scholar
• Win NN Awale S Esumi H Tezuka Y Kadota S Bioactive secondary metabolites from Boesenbergia pandurata of Myanmar and their preferential cytotoxicity against human pancreatic cancer PANC-1 cell line in nutrient-deprived medium J Nat Prod 2007 70 1582 1587 17896818
   PubMed Web of Science ®Google Scholar
• Win NN Awale S Esumi H Tezuka Y Kadota S Panduratins D–I, novel secondary metabolites from rhizomes of Boesenbergia pandurata Chem Pharm Bull 2008 56 491 496 18379096
   PubMed Web of Science ®Google Scholar
• Awale S Linn TZ Than MM Swe T Saiki I Kadota S The healing art of traditional medicines in Myanmar J Trad Med 2006 23 47 68
   Google Scholar
• Awale S Ueda J Athikomkulchai S Antiausterity agents from Uvaria dac and their preferential cytotoxic activity against human pancreatic cancer cell lines in a nutrient-deprived condition J Nat Prod 2012 75 1177 1183 22676269
   PubMed Web of Science ®Google Scholar
• Guertin DA Sabatini DM Defining the role of mTOR in cancer Cancer Cell 2007 12 9 22 17613433
   PubMed Web of Science ®Google Scholar
• Conroy T Gavoille C Samalin E Ychou M Ducreux M The role of the FOLFIRINOX regimen for advanced pancreatic cancer Curr Oncol Rep 2013 15 182 189 23341367
   PubMed Web of Science ®Google Scholar
• Saif MW Advancements in the management of pancreatic cancer: 2013 JOP 2013 14 112 118 23474549
   PubMedGoogle Scholar
• Schönthal AH Endoplasmic reticulum stress and autophagy as targets for cancer therapy Cancer Lett 2009 275 163 169 18692955
   PubMed Web of Science ®Google Scholar
• Schönthal AH Gliomas: Aggravating endoplasmic reticulum stress by combined application of bortezomib and celexoib as a novel therapeutic strategy for glioblastoma Hayat MA Tumors of the Central Nervous System Dordrecht, The Netherlands Springer 2011 1
   Google Scholar
• Yang ZJ Chee CE Huang S Sinicrope FA The role of autophagy in cancer: therapeutic implications Mol Cancer Ther 2011 10 1533 1541 21878654
   PubMed Web of Science ®Google Scholar
• Sato K Tsuchihara K Fujii S Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation Cancer Res 2007 67 9677 9684 17942897
   PubMed Web of Science ®Google Scholar
• Choi KS Autophagy and cancer Exp Mol Med 2012 44 109 120 22257886
   PubMed Web of Science ®Google Scholar
• Gozuacik D Kimchi A Autophagy as a cell death and tumor suppressor mechanism Oncogene 2004 23 2891 2906 15077152
   PubMed Web of Science ®Google Scholar
• Esumi H Lu J Kurashima Y Hanaoka T Antitumor activity of pyrvinium pamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methyl-quinolinium pamoate salt, showing preferential cytotoxicity during glucose starvation Cancer Sci 2004 95 685 690 15298733
   PubMed Web of Science ®Google Scholar
• Lu J Kunimoto S Yamazaki Y Kaminishi M Esumi H Kigamicin D, a novel anticancer agent based on a new anti-austerity strategy targeting cancer cells’ tolerance to nutrient starvation Cancer Sci 2004 95 547 552 15182438
   PubMed Web of Science ®Google Scholar
• Yardley DA Combining mTOR inhibitors with chemotherapy and other targeted therapies in advanced breast cancer: rationale, clinical experience, and future directions Breast Cancer Basic Res Treat 2013 7 7 22
   PubMedGoogle Scholar